Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis

Atherosclerosis

Volumn 259, Issue , 2017, Pages 75-82

  Li, Yunwei ^a   Zhong, Xiaoming ^a   Cheng, Guanchang ^a   Zhao, Cuihua ^a   Zhang, Lei ^a   Hong, Yan ^a   Wan, Qilin ^a   He, Ruili ^a   Wang, Zhizhong ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

All cause mortality; Cardiovascular mortality; High sensitivity C reactive protein; Meta analysis

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; FOLLOW UP; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; META ANALYSIS; MIDDLE AGED; MORTALITY; NEOPLASM; ODDS RATIO; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 85015377980     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2017.02.003     Document Type: Article

References (40)

1. [1] Pepys, M.B., Hirschfield, G.M., C-reactive protein: a critical update. J. Clin. Invest 111 (2003), 1805–1812.
2. [2] Vasto, S., Candore, G., Balistreri, C.R., Caruso, M., Colonna-Romano, G., Grimaldi, M.P., et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech. Ageing Dev. 128 (2007), 83–91.
3. [3] Woloshin, S., Schwartz, L.M., Distribution of C-reactive protein values in the United States. N. Engl. J. Med. 352 (2005), 1611–1613.
4. [4] Elias-Smale, S.E., Kardys, I., Oudkerk, M., Hofman, A., Witteman, J.C., C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis 195 (2007), e195–202.
5. [5] Ridker, P.M., A test in context: high-sensitivity C-Reactive protein. J. Am. Coll. Cardiol. 67 (2016), 712–723.
6. [6] Guo, Y.Z., Pan, L., Du, C.J., Ren, D.Q., Xie, X.M., Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J. Cancer Prev. 14 (2013), 243–248.
7. [7] Laaksonen, D.E., Niskanen, L., Nyyssonen, K., Punnonen, K., Tuomainen, T.P., Salonen, J.T., C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur. Heart J. 26 (2005), 1783–1789.
8. [8] Shinkai, S., Chaves, P.H., Fujiwara, Y., Watanabe, S., Shibata, H., Yoshida, H., et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch. Intern Med. 168 (2008), 200–206.
9. [9] Arima, H., Kubo, M., Yonemoto, K., Doi, Y., Ninomiya, T., Tanizaki, Y., et al. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 1385–1391.
10. [10] Koenig, W., Khuseyinova, N., Baumert, J., Meisinger, C., Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin. Chem. 54 (2008), 335–342.
11. [11] Makita, S., Nakamura, M., Satoh, K., Tanaka, F., Onoda, T., Kawamura, K., et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 204 (2009), 234–238.
12. [12] Elkind, M.S., Luna, J.M., Moon, Y.P., Liu, K.M., Spitalnik, S.L., Paik, M.C., et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 73 (2009), 1300–1307.
13. [13] Hamer, M., Chida, Y., Stamatakis, E., Association of very highly elevated C-reactive protein concentration with cardiovascular events and all-cause mortality. Clin. Chem. 56 (2010), 132–135.
14. [14] Ahmadi-Abhari, S., Luben, R.N., Wareham, N.J., Khaw, K.T., Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur. J. Epidemiol. 28 (2013), 541–550.
15. [15] Oluleye, O.W., Folsom, A.R., Nambi, V., Lutsey, P.L., Ballantyne, C.M., Troponin, T., B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann. Epidemiol. 23 (2013), 66–73.
16. [16] Kuoppamaki, M., Salminen, M., Vahlberg, T., Irjala, K., Kivela, S.L., Raiha, I., High sensitive C-reactive protein (hsCRP), cardiovascular events and mortality in the aged: a prospective 9-year follow-up study. Arch. Gerontol. Geriatr. 60 (2015), 112–117.
17. [17] Zuo, H., Ueland, P.M., Ulvik, A., Eussen, S.J., Vollset, S.E., Nygard, O., et al. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: the hordaland health study. Am. J. Epidemiol. 183 (2016), 249–258.
18. [18] Nisa, H., Hirata, A., Kohno, M., Kiyohara, C., Ohnaka, K., High-sensitivity C-Reactive protein and risks of all-cause and cause-specific mortality in a japanese population. Asian Pac J. Cancer Prev. 17 (2016), 2643–2648.
19. [19] Allin, K.H., Bojesen, S.E., Nordestgaard, B.G., Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27 (2009), 2217–2224.
20. [20] Morrison, L., Laukkanen, J.A., Ronkainen, K., Kurl, S., Kauhanen, J., Toriola, A.T., Inflammatory biomarker score and cancer: a population-based prospective cohort study. BMC Cancer, 16, 2016, 80.
21. [21] Yamada, S., Gotoh, T., Nakashima, Y., Kayaba, K., Ishikawa, S., Nago, N., et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: jichi Medical School Cohort Study. Am. J. Epidemiol. 153 (2001), 1183–1190.
22. [22] Kelley-Hedgepeth, A., Lloyd-Jones, D.M., Colvin, A., Matthews, K.A., Johnston, J., Sowers, M.R., et al. Ethnic differences in C-reactive protein concentrations. Clin. Chem. 54 (2008), 1027–1037.
23. [23] Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375 (2010), 132–140.
24. [24] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern Med. 151 (2009), 264–269 W64.
25. [25] Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwell, P., The Newcastle–Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed 6 April 2014).
26. [26] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
27. [27] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
28. [28] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
29. [29] Ko, Y.J., Kwon, Y.M., Kim, K.H., Choi, H.C., Chun, S.H., Yoon, H.J., et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol. Biomarkers Prev. 21 (2012), 2076–2086.
30. [30] Gaskins, A.J., Wilchesky, M., Mumford, S.L., Whitcomb, B.W., Browne, R.W., Wactawski-Wende, J., et al. Endogenous reproductive hormones and C-reactive protein across the menstrual cycle: the BioCycle Study. Am. J. Epidemiol. 175 (2012), 423–431.
31. [31] Legein, B., Temmerman, L., Biessen, E.A., Lutgens, E., Inflammation and immune system interactions in atherosclerosis. Cell Mol. Life Sci. 70 (2013), 3847–3869.
32. [32] Rosenfeld, M.E., Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr. Opin. Pharmacol. 13 (2013), 154–160.
33. [33] Koenig, W., High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int. J. Cardiol. 168 (2013), 5126–5134.
34. [34] Tracy, R.P., Psaty, B.M., Macy, E., Bovill, E.G., Cushman, M., Cornell, E.S., et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 2167–2176.
35. [35] Verhagen, S.N., Wassink, A.M., van der Graaf, Y., Visseren, F.L., C-reactive protein and incident diabetes in patients with arterial disease. Eur. J. Clin. Invest 43 (2013), 1052–1059.
36. [36] Schillaci, G., Pirro, M., C-reactive protein in hypertension: clinical significance and predictive value. Nutr. Metab. Cardiovasc Dis. 16 (2006), 500–508.
37. [37] Lu, H.H., Guo, Z.R., Hu, X.S., Wu, M., Zhou, M.H., Zhou, Z.Y., The Prospective Study of Association between C-reactive Protein and Hypertension in Community Population Zhonghua Yu Fang Yi Xue Za Zhi, vol. 47, 2013, 1026–1030.
38. [38] Mitrovic, V., Klein, H.H., Krekel, N., Kreuzer, J., Fichtlscherer, S., Schirmer, A., et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol. 94 (2005), 336–342.
39. [39] Balk, E.M., Lau, J., Goudas, L.C., Jordan, H.S., Kupelnick, B., Kim, L.U., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern Med. 139 (2003), 670–682.
40. [40] Hanefeld, M., Pfutzner, A., Forst, T., Kleine, I., Fuchs, W., Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol., 10, 2011, 65.